ANAVEX2-73 Study in Patients With Rett Syndrome

Summary

ANAVEX2-73-RS-002 is a Phase 3, double-blind, randomized, placebo-controlled dose escalation safety, tolerability and efficacy study in patients 18 years and older with RTT using endpoints including multiple clinical and exploratory molecular and biochemical measures.

Timeline

Start

2019-05-06

Primary completion

2021-09-30

Completion

2021-09-30

Drugs

Indications